Skip to main
INSP
INSP logo

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 13%
Buy 40%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Inspire Medical Systems Inc. demonstrates a positive outlook driven by a significant increase in volume at centers that have transitioned to their gen 5 system, achieving over a 20% increase in the first half of 2025 compared to the same period in 2024. The company's revenue growth is anticipated to accelerate by 12-13% year-over-year in FY2026, as management expects the impact of the gen 5 rollout and diminishing headwinds to enhance performance. Furthermore, a shift towards a favorable product mix will likely improve gross margins, providing additional leverage on profit and loss as the company expands its marketing efforts and patient awareness programs.

Bears say

Inspire Medical Systems Inc. has underperformed expectations for fiscal year 2025, primarily due to a slower-than-anticipated launch of the Inspire V system, leading the company to revise its revenue guidance downwards by $37.5 million at the midpoint. The revised earnings per share outlook has also seen a significant reduction, from a range of $2.20-$2.30 down to $0.40-$0.50, reflecting increased operational spending and lower revenue growth. Furthermore, the company's gross margin of 84.0% fell short of pre-call estimates, indicating additional operational challenges contributing to an overall impaired financial outlook.

INSP has been analyzed by 15 analysts, with a consensus rating of Buy. 13% of analysts recommend a Strong Buy, 40% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Buy based on their latest research and market trends.

According to 15 analysts, INSP has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $145.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $145.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.